As reported in the St. Louis Business Journal,  biotech startup Wugen Inc. has raised $172 million in Series B funding. The St. Louis-based company was founded on technology licensed through the Office of Technology Management at Washington University in St. Louis.

The round brings Wugen’s total capital raised to more than $200 million, one of the largest equity funding rounds ever by a St. Louis-based company.

Wugen plans to use the funding to advance the clinical development of  “natural killer” (NK) and T-cell therapies to treat various cancers. Its NK cell therapies aim to treat a wide range of hematological and solid tumor malignancies.

The company’s lead drug candidate, WU-NK-101, is in an ongoing phase 1/2 clinical trial for acute myelogenous leukemia. Wugen also plans to begin multiple solid tumor clinical trials and is moving forward with its CAR-T cell therapy, which is designed to treat T-cell leukemia and lymphoma.

Wugen currently has about 40 employees with offices in St. Louis and San Diego. The company’s St. Louis operation is located in the 4340 Duncan building in the Cortex Innovation Community.

Read the full article in the St. Louis Business Journal.